^
Association details:
Biomarker:NLRC5 overexpression
Cancer:Melanoma
Drug Class:PD1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy

Published date:
02/05/2021
Excerpt:
Melanoma tumors derived from patients responding to immunotherapy exhibited significantly higher expression of NLRC5 and MHC class I-related genes compared to non-responding patients...These results suggest that NLRC5 tumor expression, alone or together with tumor mutation load constitutes a valuable predictive biomarker for both prognosis and response to anti-CTLA-4 and potentially anti-PD1 blockade immunotherapy in melanoma patients.
DOI:
10.1038/s41598-021-82729-9